化学
第1周
髓系白血病
药效团
组蛋白脱乙酰基酶
白血病
下调和上调
髓样
组蛋白脱乙酰酶抑制剂
HDAC8型
组蛋白
癌症研究
药理学
组蛋白乙酰转移酶
乙酰化
小分子
细胞周期检查点
体外
全景望远镜
伏立诺他
体内
组蛋白脱乙酰基酶2
细胞模型
细胞周期
细胞凋亡
急性白血病
结构-活动关系
作者
Wenhui Zhang,Wenxin Yan,Tianyi Wei,Sai Che,Yangqian Sun,Aohua Xiao,Jiayu Wu,Yunzhen Zhan,Hongmei Li,Tao Lu,Yungen Xu,Hongfeng Gu,Hui Huang,Jinsong Han
标识
DOI:10.1021/acs.jmedchem.5c01789
摘要
Abstract Inhibiting Wee1 is recognized as an effective strategy for treating acute myeloid leukemia (AML). However, the compensatory activation of CHK1 may reduce the efficacy of Wee1 inhibitors in AML treatment. Given that histone deacetylase (HDAC) inhibitors downregulate CHK1 expression, the simultaneous inhibition of both Wee1 and HDAC could yield a synergistic effect. Based on this premise, we designed and synthesized a series of dual-targeting compounds by the pharmacophore combination strategy. Notably, compound 23f demonstrates significant inhibitory activity against both Wee1 and HDACs, effectively inhibiting the proliferation of MV4–11 cells. Furthermore, in the MV4–11 xenograft model, compound 23f demonstrates remarkable antitumor efficacy (TGI = 82%) at a dose of 60 mg/kg. This study identifies compound 23f as a potent dual-target inhibitor of Wee1 and HDAC, offering a novel option for the treatment of AML. Additionally, it serves as a probe for further investigation into the synergistic mechanisms between these two targets.
科研通智能强力驱动
Strongly Powered by AbleSci AI